Bobadilla María Liz, Villagra Verónica, Castro Héctor, von Horoch Marta, Araya Soraya, Deluca Gerardo, de Paula Vanessa Salete
Laboratory of Immunology, Central Laboratory of Public Health, Minister of Public Health and Social Welfare, Asunción 1429, Paraguay.
Laboratory of Molecular Virology and Parasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil.
Pathogens. 2024 Feb 27;13(3):209. doi: 10.3390/pathogens13030209.
Cervical cancer is a global health concern and ranks fourth among the most prevalent cancers in women worldwide. Human papillomavirus (HPV) infection is a known precursor of cervical cancer and preventive measures include prophylactic vaccines. This study focused on sexually active Paraguayan women aged 18-25 years, exploring the intersection of HPV vaccination and sexual behavior. Among 254 participants, 40.9% received the Gardasil-4 vaccine, with no significant differences in sexual behavior between the vaccinated and unvaccinated sexually active groups. However, a notable decrease in the prevalence of HPV among the vaccinated women highlights the efficacy of this vaccine in reducing infections. The prevalence of any HPV type was 37.5% in vaccinated participants compared to 56.7% in unvaccinated participants ( = 0.0026). High-risk HPV types showed a significant difference, with a prevalence of 26.0% in vaccinated women compared with 52.7% in unvaccinated women ( < 0.001). Although a potential decline in genital warts was observed among the vaccinated individuals, statistical significance ( = 0.0564) was not reached. Despite the challenges in achieving high vaccination coverage, the observed reduction in HPV prevalence underscores the importance of ongoing monitoring, healthcare professional recommendations, and comprehensive risk management. These findings contribute to dispelling concerns about HPV vaccination influencing sexual behavior, advocating further large-scale research to explore the impact of vaccines on various HPV types and potential cross-protection.
宫颈癌是一个全球性的健康问题，在全球女性最常见的癌症中排名第四。人乳头瘤病毒（HPV）感染是宫颈癌已知的前驱因素，预防措施包括预防性疫苗。本研究聚焦于18至25岁有性行为的巴拉圭女性，探讨HPV疫苗接种与性行为之间的关联。在254名参与者中，40.9%接种了佳达修4价疫苗，接种疫苗和未接种疫苗的有性行为组在性行为方面无显著差异。然而，接种疫苗女性中HPV流行率显著下降，突出了该疫苗在减少感染方面的有效性。接种疫苗参与者中任何HPV类型的流行率为37.5%，未接种疫苗参与者中为56.7%（P = 0.0026）。高危HPV类型存在显著差异，接种疫苗女性中的流行率为26.0%，未接种疫苗女性中为52.7%（P < 0.001）。尽管在接种疫苗者中观察到生殖器疣可能有所减少，但未达到统计学显著性（P = 0.0564）。尽管在实现高疫苗接种覆盖率方面存在挑战，但观察到的HPV流行率下降强调了持续监测、医疗保健专业人员建议和全面风险管理的重要性。这些发现有助于消除对HPV疫苗接种影响性行为的担忧，倡导进一步开展大规模研究，以探索疫苗对各种HPV类型的影响以及潜在的交叉保护作用。
